中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2009年
1期
40-41
,共2页
梁群英%冯爱菊%郭瑞珍%邱晓娣%窦颖%张玉文
樑群英%馮愛菊%郭瑞珍%邱曉娣%竇穎%張玉文
량군영%풍애국%곽서진%구효제%두영%장옥문
淋巴瘤%凋亡%XIAP%预后
淋巴瘤%凋亡%XIAP%預後
림파류%조망%XIAP%예후
Lymphoma%Apoptosis%XIAP%Prognosis
目的 探讨XIAP蛋白在非霍奇金淋巴瘤(NHL)中的表达及其临床病理意义.方法 应用TdT介导的dUTP缺口末端标记(TUNEL)技术和免疫组织化学SP法,检测79例NHL和20例良性淋巴结病变中的肿瘤细胞凋亡及XIAP蛋白的表达水平.结果 39.2%(31/79)NHL表达XIAP蛋白,而在15%(3/20)良性淋巴结病变中弱阳性表达,两者差异有统计学意义(P<0.05);XIAP在NHL中的表达与年龄、性别及免疫表型无关(P>0.05);XIAP阳性表达患者的平均生存时间明显短于无表达患者(P<0.05).结论 XIAP蛋白可能通过凋亡抑制功能在NHL的发生进展中有一定作用,并可作为判断NHL预后的参考指标.
目的 探討XIAP蛋白在非霍奇金淋巴瘤(NHL)中的錶達及其臨床病理意義.方法 應用TdT介導的dUTP缺口末耑標記(TUNEL)技術和免疫組織化學SP法,檢測79例NHL和20例良性淋巴結病變中的腫瘤細胞凋亡及XIAP蛋白的錶達水平.結果 39.2%(31/79)NHL錶達XIAP蛋白,而在15%(3/20)良性淋巴結病變中弱暘性錶達,兩者差異有統計學意義(P<0.05);XIAP在NHL中的錶達與年齡、性彆及免疫錶型無關(P>0.05);XIAP暘性錶達患者的平均生存時間明顯短于無錶達患者(P<0.05).結論 XIAP蛋白可能通過凋亡抑製功能在NHL的髮生進展中有一定作用,併可作為判斷NHL預後的參攷指標.
목적 탐토XIAP단백재비곽기금림파류(NHL)중적표체급기림상병리의의.방법 응용TdT개도적dUTP결구말단표기(TUNEL)기술화면역조직화학SP법,검측79례NHL화20례량성림파결병변중적종류세포조망급XIAP단백적표체수평.결과 39.2%(31/79)NHL표체XIAP단백,이재15%(3/20)량성림파결병변중약양성표체,량자차이유통계학의의(P<0.05);XIAP재NHL중적표체여년령、성별급면역표형무관(P>0.05);XIAP양성표체환자적평균생존시간명현단우무표체환자(P<0.05).결론 XIAP단백가능통과조망억제공능재NHL적발생진전중유일정작용,병가작위판단NHL예후적삼고지표.
Objective To investigate the expression of XIAP and its significance in non-Hodgkin's lymphomas.Methods Tdt-mediate dUTP nick end labeling(TUNEL)and immunohistoehemistry were used to study cell apoptosis and expression of XIAP in 79 non-Hodgkin's lymphoma samples and 20 benign lymph node pathological changes.Results XIAP was positive in 31 of 79(39.2%)cases of non-Hodgkin's lymphomas,but its expression was detected only in 3 of 20 cases of benign lymph node lesions(P<0.05).The expression of XIAP was irrelevant to age,gender and immune phenotype of non-Hodgkin's lymphoma (P>0.05).Furthermore,the mean survival period was significantly shorter in patients' expressing XIAP as compared with the XIAP-negative group.Conclusions Apoptosis inhibition by overexpression of XIAP might be involved in the onset and progress of non-Hodgkin's lymphoma.The expression of XIAP may be used as a reference index for evaluating prognosis of non-Hodgkin's lymphoma.